Sulcogan

Hazard statements (CLP)

H361d, H373, H400, H410

Code

Statements

H361d

Suspected of damaging the unborn child

SECTION 2: Hazards identification

Hazard statements

see section 16 : H361d - Suspected of damaging the unborn child. H373 - May cause damage to organs through prolonged or repeated exposure. H410 - Very toxic to aquatic life with long lasting effects.

Adverse physicochemical, human health and environmental effects

Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling

Hazard pictograms

GHS08 GHS09 Printing date: 16/11/2022 IT - en 1/12

Signal word

Warning

Contains

sulcotrione (ISO); 2-[2-chloro-4-(methylsulfonyl)benzoyl]cyclohexane-1,3-dione

Precautionary statements

P102 - Keep out of reach of children. P201 - Obtain special instructions before use. P260 - Do not breathe dust, fume, gas, mist, spray, vapours. P280 - Wear protective gloves, protective clothing, face protection, eye protection. P501 - Dispose of contents and container to accordance with applicable national regulations.

Supplemental label elements

EUH401 - To avoid risks to human health and the environment, comply with the instructions for use. EUH208 - Contains 1,2-benzisothiazol-3(2H)-one, sulcotrione (ISO); 2-[2-chloro-4- (methylsulfonyl)benzoyl]cyclohexane-1,3-dione. May produce an allergic reaction.

Additional information

SP 1 - Do not contaminate water with the product or its container (Do not clean application equipment near surface water/Avoid contamination via drains from farmyards and roads).

2.3 Other hazards

This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %.